Inventor · disambiguated record
Dana Kennedy
Also filed as: KENNEDY DANA · KENNEDY DANA ANN
12 granted patents·7 pending applications·91 citations·filing 2010–2024
92Inventor score
Top patents by PatentIndex Score
19 records- 0196US11077164B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2021·Granted Aug 3, 2021·3 cites·18 claims
- 0296US10940178B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2020·Granted Mar 9, 2021·4 cites·30 claims
- 0396US10722549B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEATTLE GENETICS INC·Filed 2019·Granted Jul 28, 2020·7 cites·23 claims
- 0495US11369658B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2021·Granted Jun 28, 2022·2 cites·9 claims
- 0595US10912813B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2018·Granted Feb 9, 2021·5 cites·1 claims
- 0694US10098963B2Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugatesSEATTLE GENETICS INC·Filed 2017·Granted Oct 16, 2018·10 cites·8 claims
- 0794US9713648B2Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugatesSEATTLE GENETICS INC·Filed 2015·Granted Jul 25, 2017·11 cites·4 claims
- 0894US9211319B2Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugatesSIEVERS ERIC·Filed 2010·Granted Dec 15, 2015·30 cites·17 claims
- 0992US10478469B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEATTLE GENETICS INC·Filed 2019·Granted Nov 19, 2019·6 cites·30 claims
- 1091US8758758B1Post-relapse treatment of CD30 expressing lymphomasSIEVERS ERIC·Filed 2011·Granted Jun 24, 2014·12 cites·17 claims
- 1191US2024415917A1Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugatesSEAGEN INC·Filed 2024·Application pending·0 cites
- 1285US2024139275A1Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugatesSEAGEN INC·Filed 2022·Application pending·0 cites
- 1384US11559558B2Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugatesSEAGEN INC·Filed 2022·Granted Jan 24, 2023·0 cites·30 claims
- 1472US11110179B2Combination of CD33 antibody drug conjugates with chemotherapeutic agentsSEAGEN INC·Filed 2017·Granted Sep 7, 2021·1 cites·12 claims
- 1567US2024076402A1Humanized anti-liv1 antibodies for the treatment of breast cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 1657US2023364254A1Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteinsAGENSYS INC·Filed 2021·Application pending·0 cites
- 1756US2020283540A1Humanized anti-liv1 antibodies for the treatment of breast cancerSEATTLE GENETICS INC·Filed 2018·Application pending·0 cites
- 1855US2024180906A1Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate CancerPFIZER·Filed 2022·Application pending·0 cites
- 1934US2019117787A1Combinations of cd33 antibody drug conjugates with hypomethylating agentsSEATTLE GENETICS INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →